Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GBT Global Blood Therapeutics	$68.49	$68.47	$21.65 ▼ $73.02	$4.62B	0.45	2.07 million shs	74 shs
GMAB Genmab A/S	$21.78 +0.5%	$21.66	$17.24 ▼ $28.43	$13.90B	0.95	989,805 shs	1.20 million shs
ITCI Intra-Cellular Therapies	$131.87	$131.87	$70.90 ▼ $131.98	$14.05B	0.69	1.57 million shs	N/A
TEVA Teva Pharmaceutical Industries	$15.38 -0.5%	$16.86	$12.47 ▼ $22.80	$17.72B	0.62	11.70 million shs	14.13 million shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GBT Global Blood Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
GMAB Genmab A/S	+0.51%	-6.92%	+6.56%	+1.40%	-23.01%
ITCI Intra-Cellular Therapies	0.00%	0.00%	0.00%	0.00%	+67.52%
TEVA Teva Pharmaceutical Industries	-0.49%	-6.98%	-9.90%	-5.18%	-11.71%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GBT Global Blood Therapeutics	0.3075 of 5 stars	0.0	0.0	4.0	0.0	0.0	0.6
GMAB Genmab A/S	3.6799 of 5 stars	3.3	3.0	0.0	3.9	0.0	3.1
ITCI Intra-Cellular Therapies	0.9776 of 5 stars	1.1	0.0	4.5	0.0	1.7	0.6
TEVA Teva Pharmaceutical Industries	3.9815 of 5 stars	4.6	2.0	0.0	3.4	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GBT Global Blood Therapeutics	0.00	N/A	N/A	N/A
GMAB Genmab A/S	2.64	Moderate Buy	$37.80	73.55% Upside
ITCI Intra-Cellular Therapies	2.17	Hold	$109.70	-16.81% Downside
TEVA Teva Pharmaceutical Industries	3.25	Buy	$24.71	60.69% Upside

Current Analyst Ratings Breakdown

Latest GBT, TEVA, ITCI, and GMAB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/8/2025	GMAB Genmab A/S	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$45.00 ➝ $46.00
6/26/2025	TEVA Teva Pharmaceutical Industries	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$24.00 ➝ $23.00
6/6/2025	TEVA Teva Pharmaceutical Industries	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$24.00
5/28/2025	TEVA Teva Pharmaceutical Industries	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$25.00
5/27/2025	TEVA Teva Pharmaceutical Industries	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/12/2025	TEVA Teva Pharmaceutical Industries	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$21.00 ➝ $23.00
5/8/2025	TEVA Teva Pharmaceutical Industries	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$20.00 ➝ $22.00

(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GBT Global Blood Therapeutics	$194.75M	23.73	N/A	N/A	$3.05 per share	22.46
GMAB Genmab A/S	$3.12B	4.48	$1.52 per share	14.29	$8.04 per share	2.71
ITCI Intra-Cellular Therapies	$680.50M	20.64	N/A	N/A	$6.15 per share	21.44
TEVA Teva Pharmaceutical Industries	$16.54B	1.07	$3.35 per share	4.59	$5.96 per share	2.58

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GBT Global Blood Therapeutics	-$303.09M	-$5.01	N/A	N/A	N/A	-137.30%	-170.37%	-39.24%	N/A
GMAB Genmab A/S	$1.14B	$1.76	12.38	12.24	6.58	35.11%	18.08%	14.52%	8/7/2025 (Estimated)
ITCI Intra-Cellular Therapies	-$139.67M	-$0.73	N/A	694.05	N/A	-14.07%	-9.93%	-8.38%	N/A
TEVA Teva Pharmaceutical Industries	-$1.64B	-$1.15	N/A	5.85	0.91	-0.95%	46.10%	7.18%	N/A

Latest GBT, TEVA, ITCI, and GMAB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	GMAB Genmab A/S	$0.39	N/A	N/A	N/A	$5.77 billion	N/A
7/30/2025	Q2 2025	TEVA Teva Pharmaceutical Industries	$0.64	$0.66	+$0.02	$0.24	$4.34 billion	$4.18 billion
5/8/2025	Q1 2025	GMAB Genmab A/S	$0.23	$0.31	+$0.08	$0.31	$5.17 billion	$715.00 million
5/7/2025	Q1 2025	TEVA Teva Pharmaceutical Industries	$0.47	$0.52	+$0.05	$0.18	$3.99 billion	$3.89 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GBT Global Blood Therapeutics	N/A	N/A	N/A	N/A	N/A
GMAB Genmab A/S	N/A	N/A	N/A	N/A	N/A
ITCI Intra-Cellular Therapies	N/A	N/A	N/A	N/A	N/A
TEVA Teva Pharmaceutical Industries	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GBT Global Blood Therapeutics	4.92	6.88	6.17
GMAB Genmab A/S	N/A	5.34	5.32
ITCI Intra-Cellular Therapies	N/A	7.66	7.51
TEVA Teva Pharmaceutical Industries	2.45	1.06	0.74

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GBT Global Blood Therapeutics	N/A
GMAB Genmab A/S	7.07%
ITCI Intra-Cellular Therapies	92.33%
TEVA Teva Pharmaceutical Industries	54.05%

Insider Ownership

Company	Insider Ownership
GBT Global Blood Therapeutics	4.90%
GMAB Genmab A/S	1.54%
ITCI Intra-Cellular Therapies	2.60%
TEVA Teva Pharmaceutical Industries	0.49%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GBT Global Blood Therapeutics	457	67.48 million	64.17 million	Optionable
GMAB Genmab A/S	2,682	641.54 million	631.66 million	Optionable
ITCI Intra-Cellular Therapies	560	106.52 million	103.56 million	Optionable
TEVA Teva Pharmaceutical Industries	36,830	1.15 billion	1.14 billion	Optionable

GBT, TEVA, ITCI, and GMAB Headlines

Recent News About These Companies

Comparing Teva Pharmaceutical Industries (NYSE:TEVA) and Globeimmune (OTCMKTS:GBIM)

August 2 at 2:23 AM | americanbankingnews.com

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Shares Purchased by King Wealth Management Group

August 1 at 6:35 AM | marketbeat.com

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Given Average Recommendation of "Buy" by Analysts

August 1 at 3:29 AM | americanbankingnews.com

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Given Average Rating of "Buy" by Analysts

August 1 at 3:25 AM | marketbeat.com

Teva's Big Pharma Comeback: Why I Think The Market Is Still Missing The Upside

July 31 at 5:48 PM | seekingalpha.com

TEVA Q2 Earnings Beat, Revenues Miss on Lower Generics Sales

July 31 at 1:41 PM | zacks.com

Teva Pharmaceutical Industries (NYSE:TEVA) Releases FY 2025 Earnings Guidance

July 31 at 7:38 AM | marketbeat.com

Zurcher Kantonalbank Zurich Cantonalbank Buys 36,843 Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

July 31 at 5:01 AM | marketbeat.com

Teva Pharm's second-quarter profit boosted by branded drugs, US tariff questions remain

July 30 at 2:29 PM | msn.com

Teva CEO: Our supply chain puts us in a strong position

July 30 at 1:04 PM | youtube.comY

Teva Pharmaceutical Industries Limited (TEVA) Q2 2025 Earnings Call Transcript

July 30 at 12:15 PM | seekingalpha.com

Compared to Estimates, Teva Pharmaceutical Industries (TEVA) Q2 Earnings: A Look at Key Metrics

July 30 at 10:36 AM | zacks.com

Teva Pharma shares climb 3% after Q2 earnings surpass expectations

July 30 at 9:27 AM | msn.com

Teva posts Q2 revenue miss as generic products underperform

July 30 at 9:27 AM | msn.com

Teva Pharmaceutical Industries Ltd Reports Q2 2025 Earnings: GAAP EPS of $0. ...

July 30 at 7:43 AM | gurufocus.com

Teva Pharm Q2 profit beats estimates as branded drugs gain

July 30 at 7:21 AM | reuters.com

36,300 Shares in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Bought by Wellington Shields & Co. LLC

July 30 at 4:11 AM | marketbeat.com

Monaco Asset Management SAM Buys Shares of 225,000 Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

July 30 at 4:11 AM | marketbeat.com

XTX Topco Ltd Makes New $2.46 Million Investment in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

July 30 at 4:11 AM | marketbeat.com

Generic Revlimid Fades, But Teva's Broader Generics Outlook Remains Strong

July 29, 2025 | benzinga.com

Picton Mahoney Asset Management Reduces Position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

July 29, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GBT, TEVA, ITCI, and GMAB Company Descriptions

Global Blood Therapeutics NASDAQ:GBT

Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.

Genmab A/S NASDAQ:GMAB

$21.78 +0.11 (+0.51%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$21.78 0.00 (0.00%)

As of 08/1/2025 05:59 PM Eastern

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Intra-Cellular Therapies NASDAQ:ITCI

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

Teva Pharmaceutical Industries NYSE:TEVA

$15.38 -0.07 (-0.45%)

Closing price 08/1/2025 03:59 PM Eastern

Extended Trading

$15.42 +0.03 (+0.23%)

As of 08/1/2025 07:54 PM Eastern

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time